Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Omalizumab (Xolair), an immunomodulator, works differently from other anti-inflammatory medications for asthma. Xolair blocks the activity of IgE (a protein that is overproduced in people with ...

Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication. The Food and Drug Administration (FDA ...

The company’s top growth drivers were Phesgo, Vabysmo, Xolair, Hemlibra and Xofluza (influenza). These five drugs (in unison) generated sales of CHF 3.6 billion, reflecting an increase of CHF 0. ...

On World Asthma Day, a suburban family is sounding the alarm on how an insurance change could impact life-saving care for their daughter.

The dispute over who administers these medications follows a long list complaints over health plan rules that seek to ...

New findings suggest asthma may be reversible in some cases, offering hope for long-term remission and a shift in treatment ...

Pulmonologists alarmed by climate-linked asthma surge, find hope in novel medications: Nandita Vijayasimha, Bengaluru Tuesday, May 6, 2025, 08:00 Hrs [IST] Pulmonologists associat ...

eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion ...

Living with severe food allergies clouds every day with fear. When the tiniest smidge of peanuts or wheat could kill you, ...

The new-generation drug – also known as QGE031 – binds more tightly to IgE than Roche-partnered Xolair (omalizumab), and that suggests it could be more effective as a treatment for CSU ...

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 ...